Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset

Authors
Elkhalifa, MarwaOrbai, Ana-MariaMagder, Laurence S.Petri, MichelleAlarcon, Graciela S.Gordon, CarolineMerrill, JoanFortin, Paul R.Bruce, Ian N.Isenberg, DavidWallace, DanielNived, OlaRamsey-Goldman, RosalindBae, Sang-CheolHanly, John G.Sanchez-Guerrero, JorgeClarke, Ann E.Aranow, CynthiaManzi, SusanUrowitz, MurrayGladman, Dafna D.Kalunian, KenWerth, Victoria P.Zoma, AsadBernatsky, SashaKhamashta, MuntherJacobsen, SorenBuyon, Jill P.Dooley, Mary Annevan Vollenhoven, RonaldGinzler, EllenStoll, ThomasPeschken, ChristineJorizzo, Joseph L.Callen, Jeffery P.Lim, SamInanc, MuratKamen, Diane L.Rahman, AnisurSteinsson, KristjanFranks, Andrew G., Jr.
Issue Date
Jul-2021
Publisher
SAGE PUBLICATIONS LTD
Keywords
Systemic lupus erythematosus; antiphospholipid antibodies; classification criteria; anti-beta 2 glycoprotein IgA
Citation
LUPUS, v.30, no.8, pp.1283 - 1288
Indexed
SCIE
SCOPUS
Journal Title
LUPUS
Volume
30
Number
8
Start Page
1283
End Page
1288
URI
https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/987
DOI
10.1177/09612033211014248
ISSN
0961-2033
Abstract
Objective Anti-beta 2 glycoprotein I IgA is a common isotype of anti-beta 2 glycoprotein I in SLE. Anti-beta 2 glycoprotein I was not included in the American College of Rheumatology (ACR) SLE classification criteria, but was included in the Systemic Lupus International Collaborating Clinics (SLICC) criteria. We aimed to evaluate the prevalence of anti-beta 2-glycoprotein I IgA in SLE versus other rheumatic diseases. In addition, we examined the association between anti-beta 2 glycoprotein I IgA and disease manifestations in SLE. Methods The dataset consisted of 1384 patients, 657 with a consensus physician diagnosis of SLE and 727 controls with other rheumatic diseases. Anti-beta 2 glycoprotein I isotypes were measured by ELISA. Patients with a consensus diagnosis of SLE were compared to controls with respect to presence of anti-beta 2 glycoprotein I. Among patients with SLE, we assessed the association between anti-beta 2 glycoprotein I IgA and clinical manifestations. Results The prevalence of anti-beta 2 glycoprotein I IgA was 14% in SLE patients and 7% in rheumatic disease controls (odds ratio, OR 2.3, 95% CI: 1.6, 3.3). It was more common in SLE patients who were younger patients and of African descent (p = 0.019). Eleven percent of SLE patients had anti-beta 2 glycoprotein I IgA alone (no anti-beta 2 glycoprotein I IgG or IgM). There was a significant association between anti-beta 2 glycoprotein I IgA and anti-dsDNA (p = 0.001) and the other antiphospholipid antibodies (p = 0.0004). There was no significant correlation of anti-beta 2 glycoprotein I IgA with any of the other ACR or SLICC clinical criteria for SLE. Those with anti-beta 2 glycoprotein I IgA tended to have a history of thrombosis (12% vs 6%, p = 0.071), but the difference was not statistically significant. Conclusion We found the anti-beta 2 glycoprotein I IgA isotype to be more common in patients with SLE and in particular, with African descent. It could occur alone without other isotypes.
Files in This Item
Go to Link
Appears in
Collections
서울 의과대학 > 서울 내과학교실 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Bae, Sang Cheol photo

Bae, Sang Cheol
COLLEGE OF MEDICINE (DEPARTMENT OF INTERNAL MEDICINE)
Read more

Altmetrics

Total Views & Downloads

BROWSE